PALBOCICLIB (Ibrance) prior authorization at Regence
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Regence requires Kinase Inhibitor prior-authorization documentation for PALBOCICLIB (Ibrance): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Regence reviews PALBOCICLIB (Ibrance) prior authorizations against its medical policy for Kinase Inhibitor. Regence-specific context: BCBS licensee operating in Oregon, Washington (Clark/Cowlitz counties), Idaho, and Utah (~3.1M members). Subsidiary of Cambia Health Solutions. Prime Therapeutics PBM. Each state's DOI handles complaints for policies issued in that state.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Kinase Inhibitor
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Regence's medical policy URL referenced in the cover letter
Regence's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Cross-state coordination for multi-state members (OR/WA/ID/UT)
- Step therapy via Prime Therapeutics
- Behavioral health network adequacy
- Specialty drug PA
PALBOCICLIB (Ibrance)-specific denial patterns and context
Across payers (not just Regence), PALBOCICLIB (Ibrance)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Step therapy requiring endocrine monotherapy first
- Combination partner not formulary (specific AI denied)
- Continuation beyond progression denied
- Specialty pharmacy network restriction
Brand: Ibrance. CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer. First-in-class. PALOMA trial series. Loss of exclusivity expected ~2027.
Manufacturer patient-assistance program: Pfizer Oncology Together — relevant when a Regence denial sticks and the patient needs bridge access while appealing.
How Regence approaches Specialty pharmacy drugs PAs
Regence's Specialty pharmacy drugs reviewer typically anchors PALBOCICLIB (IBRANCE) prior-auth decisions on step therapy via prime therapeutics and specialty drug pa. Pharmacy-benefit review for PALBOCICLIB (IBRANCE) at Regence is routed through Prime Therapeutics. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Regence routes specialty-pharmacy denials through a separate appeal queue from medical-benefit denials — verify the appeal goes to the correct queue or it can be administratively denied for "wrong path". Regence is domiciled in OR, so unresolved appeals escalate to the OR insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). BCBS licensee operating in Oregon, Washington (Clark/Cowlitz counties), Idaho, and Utah (~3.
If the PA is denied
Regence gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.regence.com/provider) with the same packet plus a peer-reviewed citation supporting PALBOCICLIB (Ibrance)for the patient's indication.
Contact Regence
- Provider portal: https://www.regence.com/provider
Frequently asked questions
What documentation does Regence need for PALBOCICLIB (Ibrance) prior auth?
Regence's typical PA packet for PALBOCICLIB (Ibrance): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Kinase Inhibitor, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Regence?
Standard PALBOCICLIB (Ibrance) PA decisions at Regence: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Regence most often reject PALBOCICLIB (Ibrance) for?
Across Regence's book the common rejection patterns include: Cross-state coordination for multi-state members (OR/WA/ID/UT); Step therapy via Prime Therapeutics; Behavioral health network adequacy. For PALBOCICLIB (Ibrance) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Which specialty pharmacy will Regence require for PALBOCICLIB (IBRANCE)?
Regence contracts with a specific specialty-pharmacy network — using an out-of-network specialty pharmacy is a common denial cause that is administrative rather than medical-necessity. Call the prior-auth line on the back of the member card to confirm the in-network specialty pharmacy for PALBOCICLIB (IBRANCE) before submission. Note that REMS-restricted PALBOCICLIB (IBRANCE) variants (where applicable) further narrow the in-network pharmacy list. Pharmacy-benefit handling is routed through Prime Therapeutics. External-review escalation for Regence fully-insured policies sits with the OR insurance department.
How do I prep for a peer-to-peer with Regence on PALBOCICLIB (Ibrance)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the PALBOCICLIB (Ibrance) PA packet
Open ApprovalHelp — generate a PALBOCICLIB (Ibrance) prior-auth packet tailored to Regence's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com